pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

15 catalysts · 7 phase 2 initiation · 3 phase 1 2 initiation · 2 phase 1 initiation · 1 phase 2 3 completion · 1 phase 2 completion · 1 phase 3 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 17 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
TA: oncology×from 2026-04-27×to 2026-04-27×clear all
type
  • phase 2 initiation7
  • phase 1 2 initiation3
  • phase 1 initiation2
  • phase 2 3 completion1
  • phase 2 completion1
  • phase 3 completion1
therapy area
  • Oncology15
  • Infectious Disease7
  • Dermatology6
  • Cardiology4
  • Immunology4
  • Ophthalmology2
  • Pain2
  • Pulmonology2
  • Women's Health1

Week of Apr 27, 2026

15
›Apr 27, 2026phase 1 initiation106d agoCity of Hope — CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] (Phase I Trial Initiation)CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone]

Therapy area: Oncology. Indication: Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Follicular Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), T-Cell Lymphomas

full page →CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] →source: globaldata
›Apr 27, 2026phase 1 initiation106d agoNational Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)Autologous B7-H3 CAR T

Therapy area: Oncology. Indication: Neuroendocrine Cancer, Small-Cell Lung Cancer, Solid Tumor

full page →Autologous B7-H3 CAR T →source: globaldata
›Apr 27, 2026phase 1 2 initiation106d agoNational Institutes of Health Clinical Center — azacitidine (Phase I/II Trial Initiation)Onureg

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

full page →Onureg →source: globaldata
›Apr 27, 2026phase 1 2 initiation106d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — EBTATE (Phase I/II Trial Initiation)EBTATE

Therapy area: Oncology. Indication: Thyroid Cancer

full page →EBTATE →source: globaldata
›Apr 27, 2026phase 1 2 initiation106d agoNational Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)sacituzumab govitecan

Therapy area: Oncology. Indication: Neuroendocrine Cancer, Neuroendocrine Carcinoma, Small-Cell Lung Cancer

full page →sacituzumab govitecan →source: globaldata
›Apr 27, 2026phase 2 completion106d agoPt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)nivolumab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer

full page →nivolumab →source: globaldata
›Apr 27, 2026phase 2 initiation106d agoShanghai Henlius Biotech Inc — HLX-35 (Phase II Trial Initiation)HLX-35

Therapy area: Oncology. Indication: Solid Tumor, Squamous Non-Small Cell Lung Cancer

full page →HLX-35 →source: globaldata
›Apr 27, 2026phase 2 initiation106d agoJiangsu Hengrui Pharmaceuticals Co Ltd — HRS-3738 (Phase II Trial Initiation)HRS-3738

Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

full page →HRS-3738 →source: globaldata
›Apr 27, 2026phase 2 initiation106d agoWeifang Yidu Central Hospital — liposome bupivacaine (Phase II Trial Initiation)liposome bupivacaine

Therapy area: Oncology. Indication: Lung Cancer

full page →liposome bupivacaine →source: globaldata
›Apr 27, 2026phase 2 initiation106d agoNational Cancer Institute US — busulfan (Phase II Trial Initiation)busulfan

Therapy area: Oncology. Indication: Blood Cancer, Hematological Tumor, Leukemia, Lymphoma

full page →busulfan →source: globaldata
›Apr 27, 2026phase 2 initiation106d agoJiangsu Hengrui Pharmaceuticals Co Ltd — fruquintinib (Phase II Trial Initiation)fruquintinib

Therapy area: Oncology. Indication: Colorectal Cancer

full page →fruquintinib →source: globaldata
›Apr 27, 2026phase 2 initiation106d agoNational Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)cyclophosphamide

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

full page →cyclophosphamide →source: globaldata
›Apr 27, 2026phase 2 initiation106d agoChongqing Cancer Hospital — ondansetron (Phase II Trial Initiation)ondansetron ODT

Therapy area: Oncology. Indication: Ovarian Cancer

full page →ondansetron ODT →source: globaldata
›Apr 27, 2026phase 2 3 completion106d agoAnthem Biosciences Ltd — berubicin hydrochloride (Phase II/III Trial Completion)berubicin hydrochloride

Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Recurrent Glioblastoma Multiforme (GBM)

full page →berubicin hydrochloride →source: globaldata
›Apr 27, 2026phase 3 completion106d agoCellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)elranatamab

Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

full page →elranatamab →source: globaldata